Skip to main content

Table 5 Mean changes in HRQoL scores from baseline to study phase completion (week 16) by categories of change in the patient global assessment of disease activity, all dose groups combined

From: Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds

  Categories of change in patient global assessment of disease activity
  > +10 (n = 27) +10 to -10 (n = 64) -11 to -20 (n = 27) -21 to -40 (n = 41) < -40 (n = 23) F p-value
PRO Instruments        
SF-36        
Physical functioning -0.9 (19.7) 3.2 (14.2) 10.9 (19.1) 8.3 (17.3) 18.0 (22.4) 4.2 0.0029
Role physical -0.6 (14.8) 9.4 (19.4) 9.3 (24.1) 6.9 (19.8) 26.1 (30.5) 5.2 0.0006
Bodily pain -6.9 (11.4) 4.5 (17.1) 11.7 (17.5) 18.1 (13.6) 29.9 (21.9) 19.9 0.0000
General health -3.9 (11.9) 0.5 (12.5) 4.4 (16.9) 5.3 (12.2) 14.4 (16.5) 6.7 0.0001
Vitality -3.9 (13.1) 4.4 (17.7) 8.8 (21.2) 7.2 (18.0) 21.7 (25.7) 6.1 0.0001
Social functioning -6.9 (19.4) 2.1 (21.1) 5.6 (34.1) 10.7 (18.9) 16.8 (35.7) 3.6 0.0081
Role emotional -7.1 (16.3) 2.9 (27.3) 7.1 (31.2) 4.9 (20.0) 18.8 (27.9) 3.4 0.0101
Mental health -1.1 (12.4) 3.0 (17.4) 1.4 (22.3) 6.7 (16.1) 11.9 (21.5) 2.1 0.0827
Physical summary -0.6 (5.9) 1.9 (4.7) 4.5 (6.0) 4.2 (5.7) 9.4 (8.8) 10.4 0.0000
Mental summary -2.7 (6.9) 1.2 (10.2) 1.4 (12.9) 2.9 (8.7) 7.1 (13.3) 2.9 0.0219
HAQ-DI 0.01 (0.31) -0.12 (0.37) -0.32 (0.4) -0.35 (0.40) -0.64 (0.58) 10.4 0.0000
FACIT-Fatigue -1.1 (6.4) 1.94 (7.5) 5.9 (7.4) 3.78 (6.3) 10.72 (9.1) 9.8 0.0000